Table 2 Summary of efficacy data

Overall objective responses (ORR, 95% CI)

8 (27.6%, 95% CI 12.73–47.2%)

Confirmed partial response (ORR, 95% CI)

6 (20.7%, 95% CI 8–39.7%)

 Complete response

0

 Partial response

8 (27.6%)

 Stable disease

17 (58.6%)

 Progressive disease

4 (13.8%)

Disease control rate

25/29 (86.2%, 95% CI 68.3–96.1%)

Median progression-free survival

3.7 months (95% CI 3.4–5.7 months)

Median overall survival

9.1 months (95% CI 5.8–20.2 months)

4-month PFS rate

13/29 (44.8%, 95% CI 26.5–64.3%)